| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
95,223 |
83,407 |
$5.05M |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
39,696 |
36,513 |
$3.25M |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
33,541 |
28,764 |
$2.00M |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
29,985 |
26,520 |
$1.99M |
| 87634 |
|
30,266 |
26,459 |
$1.48M |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
7,726 |
4,964 |
$1.04M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
17,563 |
15,729 |
$620K |
| 99215 |
Prolong outpt/office vis |
7,369 |
6,464 |
$538K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
9,223 |
7,667 |
$458K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
7,975 |
7,431 |
$430K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
14,713 |
12,658 |
$423K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
5,230 |
4,543 |
$382K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
8,778 |
7,339 |
$296K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
23,205 |
10,776 |
$255K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
22,211 |
20,036 |
$234K |
| 87481 |
|
2,004 |
1,701 |
$224K |
| 99205 |
Prolong outpt/office vis |
1,667 |
1,536 |
$181K |
| 87653 |
|
7,274 |
6,119 |
$179K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
5,749 |
4,839 |
$141K |
| 87529 |
|
2,346 |
1,982 |
$128K |
| 87486 |
|
5,044 |
4,230 |
$120K |
| 87581 |
|
4,925 |
4,224 |
$119K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
3,808 |
3,325 |
$110K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
3,798 |
3,317 |
$110K |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
3,780 |
2,803 |
$93K |
| 81025 |
|
13,190 |
11,375 |
$68K |
| 87640 |
|
2,107 |
1,777 |
$59K |
| 87511 |
|
1,972 |
1,673 |
$55K |
| 82075 |
|
3,044 |
2,560 |
$32K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
729 |
687 |
$26K |
| 0012A |
|
886 |
803 |
$23K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
7,395 |
5,612 |
$20K |
| 0011A |
|
904 |
851 |
$20K |
| 81003 |
|
10,188 |
8,910 |
$18K |
| 80305 |
|
1,992 |
1,573 |
$18K |
| 80348 |
|
1,178 |
914 |
$16K |
| 71046 |
Radiologic examination, chest; 2 views |
714 |
643 |
$13K |
| 0001A |
|
376 |
340 |
$13K |
| 0002A |
|
324 |
270 |
$11K |
| 87801 |
Infectious agent detection by nucleic acid; amplified probe, multiple organisms |
239 |
199 |
$8K |
| 93000 |
|
656 |
598 |
$8K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
607 |
480 |
$5K |
| 94664 |
|
496 |
416 |
$4K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
194 |
150 |
$3K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
87 |
83 |
$3K |
| M0243 |
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring |
17 |
12 |
$3K |
| 87807 |
|
257 |
228 |
$3K |
| 0064A |
|
79 |
72 |
$3K |
| 90833 |
Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) |
188 |
143 |
$3K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
2,264 |
1,880 |
$3K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
3,045 |
2,760 |
$2K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
142 |
137 |
$2K |
| 80076 |
|
198 |
174 |
$1K |
| 82962 |
|
554 |
481 |
$1K |
| 36415 |
Collection of venous blood by venipuncture |
631 |
546 |
$1K |
| 90686 |
|
61 |
59 |
$856.39 |
| 73630 |
|
42 |
41 |
$764.40 |
| 0071A |
|
18 |
18 |
$747.44 |
| A7003 |
Administration set, with small volume nonfiltered pneumatic nebulizer, disposable |
546 |
446 |
$545.31 |
| 90715 |
|
15 |
14 |
$506.24 |
| 91301 |
|
1,524 |
1,309 |
$482.04 |
| 99173 |
|
390 |
347 |
$425.24 |
| 86769 |
|
29 |
19 |
$421.30 |
| 74018 |
|
13 |
13 |
$247.65 |
| 99051 |
|
56 |
43 |
$240.84 |
| 73610 |
|
12 |
12 |
$235.20 |
| 73140 |
|
13 |
12 |
$188.32 |
| 80053 |
Comprehensive metabolic panel |
14 |
12 |
$138.84 |
| 69209 |
|
16 |
13 |
$118.65 |
| A6449 |
Light compression bandage, elastic, knitted/woven, width greater than or equal to three inches and less than five inches, per yard |
385 |
330 |
$47.61 |
| 99000 |
|
2,109 |
1,938 |
$33.75 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
141 |
119 |
$7.88 |
| A9150 |
Non-prescription drugs |
2,408 |
2,021 |
$6.56 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
489 |
386 |
$1.96 |
| 91300 |
|
727 |
595 |
$1.21 |
| 91306 |
|
68 |
65 |
$0.00 |
| 91307 |
|
42 |
39 |
$0.00 |
| S0119 |
Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) |
125 |
111 |
$0.00 |